Gencor PEA Ingredient May Provide Migraine Relief
A recent human clinical trial has found that Gencor's palmitoylethanolamide (PEA) ingredient, Levagen+, is a safe and effective supplement to help reduce the discomfort and duration of migraines. Published in the Pharmaceuticals journal, the double-blind, placebo-controlled clinical trail investigated the effectiveness of PEA for pain reduction and duration during a migraine. Once migraine symptoms began, participants were given 600mg of PEA or a placebo (maltodextrin) and recorded a visual analog scale (VAS) for pain every 30 minutes for four hours or until the migraine ended. A second supplement was given to participants experiencing migraines two hours after the initial dose. The study concluded that Levagen+ led to participants having a lower VAS score for pain at 1.5 and 4 hours and it resolved more headaches after 2 and 8 hours than the placebo.
Ahiflower Oil Recognized as Sustainable Alternative to Marine Omega-3s
In a peer-reviewed scientific literature review published in Current Opinion in Clinical Nutrition and Metabolic Care, UK lipid researcher Dr. Ella Baker, Ph.D., addresses concerns on the sustainability of marine omega-3 sources. The premise: Traditional sources of very long-chain polyunsaturated fatty acids (VLC PUFA, namely EPA and DHA) are no longer sustainable. The article presents three alternative categories of direct omega-3 sources that do not involve wild-harvesting and processing oily forage fish from the oceans (typically anchovies, sardines, herring, or menhaden).
- Plant-based Ahiflower oil from Natures Crops, with the highest combined omega-3 SDA and GLA content.
- Microalgae-derived EPA/DHA sources.
- Genetically modified canola or camelina seed sources.
Natures Crops said this is the first omega-3 metabolism literature review article recognizing recent scientific publications describing Ahiflower oil’s differential effects and metabolic fate vs. EPA/DHA sources. Take a deeper dive into the findings here.
Study Underlines Role of Prebiotics in Supporting GI and Sleep Health
Clasado Biosciences announced the publication of a new Real World Evidence (RWE) study conducted in collaboration with the Primary Care Society for Gastroenterology (PCSG) featuring its prebiotic ingredient, Bimuno GOS. The study provides particular focus on common GI symptoms and sleep. Key findings reveal significant improvements in Quality of Life (QoL) across GI health and sleep for participants with diagnosed or self-diagnosed Irritable Bowel Syndrome (IBS) and sleep disturbances. "RWE studies are extremely useful in understanding the effects and benefits of Bimuno GOS,” said Dr. Lucien Harthoorn, R&D Director at Clasado. “Clinical trials are under controlled and ideal conditions, where RWE brings insight into how a product can support users in day-to-day use. Bimuno GOS stands out as the most studied prebiotic ingredient of its kind, and this RWE study further strengthens that research.The study was conducted with qualitative feedback from over 1,170 Bimuno users. For health and nutrition formulators engaged in the development of gut health-supporting products, primarily targeting digestive health, this research will be of interest as it confirms Bimuno GOS as a strong science-backed choice of prebiotic ingredient.”
